Company intelligence / Profile preview

SHU studio

Huzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Shuwen Biotech develops and markets innovative precision diagnostic tests focused on women’s health, especially breast cancer risk assessment, early screening, molecular typing/subtyping of cancers such as triple-negative breast cancer, reproductive health testing, prenatal/newborn genetic disease screening. The company’s MammaTyper test can predict low recurrence risk in certain cancers. It holds patents on gene mutation detection kits/methods. Its products are used clinically across China.

Therapeutic areas: Infectious DiseasesWomen's HealthOncology
Modalities: Molecular diagnosticsImmunodiagnosisPoint-of-care testing (POCT)Nucleic acid extraction technologies
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on SHU studio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHU studio.

Explore the full profile